Treatment of coronary heart disease in end-stage renal disease (dialysis)
- Alfred K Cheung, MD
Alfred K Cheung, MD
- Professor of Medicine
- University of Utah School of Medicine
- William L Henrich, MD, MACP
William L Henrich, MD, MACP
- University of Texas Health Science Center at San Antonio
- Section Editors
- Jeffrey S Berns, MD
Jeffrey S Berns, MD
- Section Editor — Dialysis
- Professor of Medicine
- Perelman School of Medicine at the University of Pennsylvania
- Steve J Schwab, MD
Steve J Schwab, MD
- Editor-in-Chief — Nephrology
- Section Editor — Dialysis
- University of Tennessee Health Science Center
- Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC
Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC
- Editor-in-Chief — Cardiovascular Medicine
- Section Editor — Coronary Heart Disease; Myopericardial Disease
- Professor of Medicine
- Mayo Medical School
Cardiovascular disease (CVD) is the single best predictor of mortality in patients with end-stage renal disease (ESRD) as it accounts for almost 50 percent of deaths [1-4]. Of the cardiovascular deaths, approximately 20 percent can be attributed to the consequences of coronary heart disease (CHD). Patients with varying degrees of chronic kidney disease (CKD), but not yet dialysis dependent, also have a markedly increased risk of morbidity and mortality from CVD, including CHD. (See "Patient survival and maintenance dialysis" and "Chronic kidney disease and coronary heart disease".)
Most of the issues relating to CHD are similar in patients with and without renal failure. This topic review will emphasize those features of the treatment of CHD that distinguish the dialysis patient from those without kidney disease. Related issues, such as secondary prevention and diagnosis of CHD in dialysis patients, are presented separately. (See "Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)" and "Risk factors and epidemiology of coronary heart disease in end-stage renal disease (dialysis)" and "Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)".)
There are two types of angina resulting from CHD, stable and unstable:
●Stable angina refers to chest discomfort that occurs predictably and reproducibly at a certain level of exertion and is relieved with rest or nitroglycerin.
●Unstable angina is an acute coronary syndrome that encompasses a variety of clinical conditions, including the new onset of angina, rest angina, an accelerating pattern of previously stable angina, post-myocardial infarction (MI) angina, and angina after a revascularization procedure. (See "Classification of unstable angina and non-ST elevation myocardial infarction".)
- Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238.
- Herzog CA. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 2003; 14:2556.
- Afzali B, Haydar AA, Vinen K, Goldsmith DJ. From Finland to fatland: beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol 2004; 15:2161.
- Habib AN, Baird BC, Leypoldt JK, et al. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2006; 21:2881.
- Sorrell VL. Diagnostic tools and management strategies for coronary artery disease in patients with end-stage renal disease. Semin Nephrol 2001; 21:13.
- Cice G, Di Benedetto A, D'Andrea A, et al. Sustained-release diltiazem reduces myocardial ischemic episodes in end-stage renal disease: a double-blind, randomized, crossover, placebo-controlled trial. J Am Soc Nephrol 2003; 14:1006.
- K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.
- Jeremias A, Bhatt DL, Chew DP, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol 2002; 89:1209.
- Best PJ, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003; 146:345.
- Frilling B, Zahn R, Fraiture B, et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol 2002; 89:450.
- Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003; 41:718.
- Khaja A, Garg R, Govindarajan G, et al. Percutaneous coronary intervention and the use of glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease on dialysis: a single center experience. Hemodial Int 2008; 12 Suppl 2:S2.
- Tsai TT, Maddox TM, Roe MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 2009; 302:2458.
- Coritsidis G, Sutariya D, Stern A, et al. Does timing of dialysis in patients with ESRD and acute myocardial infarcts affect morbidity or mortality? Clin J Am Soc Nephrol 2009; 4:1324.
- Ifudu O, Miles AM, Friedman EA. Hemodialysis immediately after acute myocardial infarction. Nephron 1996; 74:104.
- Herzog CA, Ma JZ, Collins AJ. Long-term outcome of dialysis patients in the United States with coronary revascularization procedures. Kidney Int 1999; 56:324.
- Rinehart AL, Herzog CA, Collins AJ, et al. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis 1995; 25:281.
- Kahn JK, Rutherford BD, McConahay DR, et al. Short- and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients. Am Heart J 1990; 119:484.
- Reusser LM, Osborn LA, White HJ, et al. Increased morbidity after coronary angioplasty in patients on chronic hemodialysis. Am J Cardiol 1994; 73:965.
- Jahangiri M, Wright J, Edmondson S, Magee P. Coronary artery bypass graft surgery in dialysis patients. Heart 1997; 78:343.
- Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after coronary revascularization among patients with kidney disease. Circulation 2004; 110:1890.
- Witczak B, Hartmann A, Svennevig JL. Multiple risk assessment of cardiovascular surgery in chronic renal failure patients. Ann Thorac Surg 2005; 79:1297.
- Charytan DM, Kuntz RE. Risks of coronary artery bypass surgery in dialysis-dependent patients--analysis of the 2001 National Inpatient Sample. Nephrol Dial Transplant 2007; 22:1665.
- Chang TI, Shilane D, Kazi DS, et al. Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol 2012; 23:2042.
- Aoyama T, Ishii H, Toriyama T, et al. Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J 2008; 72:56.
- Halkin A, Selzer F, Marroquin O, et al. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. J Invasive Cardiol 2006; 18:577.
- Nevis IF, Mathew A, Novick RJ, et al. Optimal method of coronary revascularization in patients receiving dialysis: systematic review. Clin J Am Soc Nephrol 2009; 4:369.
- Szczech LA, Reddan DN, Owen WF, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 2001; 60:292.
- Shroff GR, Solid CA, Herzog CA. Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States. Circulation 2013; 127:1861.
- Owen CH, Cummings RG, Sell TL, et al. Coronary artery bypass grafting in patients with dialysis-dependent renal failure. Ann Thorac Surg 1994; 58:1729.
- Ahmed WA, Kirshenbaum JM. Outcome of coronary artery angioplasty in hemodialysis patients. Semin Dial 1994; 7:96.
- Yachi S, Tanabe K, Tanimoto S, et al. Clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents versus bare-metal stents in hemodialysis patients. Am J Kidney Dis 2009; 54:299.
- Das P, Moliterno DJ, Charnigo R, et al. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J Invasive Cardiol 2006; 18:405.
- Weathers LW, Ziada KM. Drug-eluting stents in patients with end-stage renal disease. Minerva Cardioangiol 2008; 56:117.
- Hiremath S, Holden RM, Fergusson D, Zimmerman DL. Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin J Am Soc Nephrol 2009; 4:1347.
- Kaufman JS, O'Connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14:2313.
- Herzog CA. The optimal method of coronary revascularization in dialysis patients: choosing between a rock and a hard place. Int J Artif Organs 2000; 23:215.
- Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339:799.
- Chertow GM, Normand SL, Silva LR, McNeil BJ. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis 2000; 35:1044.
- Iseki K, Fukiyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis 2000; 36:820.
- Herzog CA, Littrell K, Arko C, et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007; 116:1465.
- Baber U, Kini AS, Sharma SK, et al. Thrombolysis In Myocardial Infarction (TIMI) risk score and mortality in patients with advanced chronic kidney disease and on dialysis. Am J Cardiol 2009; 103:1513.
- PHARMACOLOGIC TREATMENT OF STABLE CORONARY HEART DISEASE
- Antianginal therapy
- Anemia therapy
- Blood pressure control
- Antiplatelet therapy
- Risk factor reduction
- PHARMACOLOGIC TREATMENT OF UNSTABLE CORONARY HEART DISEASE
- Glycoprotein IIb/IIIa inhibitors
- Timing and performance of hemodialysis session
- INVASIVE MANAGEMENT
- Optimal method of coronary revascularization
- Choice of intracoronary stent
- Follow-up issues
- SUMMARY AND RECOMMENDATIONS
- Pharmacologic treatment of stable disease
- Pharmacologic treatment of unstable disease
- Invasive management